Nordtreat Has Appointed Outi Kallio as the New CEO
3.9.2024 07:50:00 EEST | Business Wire | Press release
The Finnish technology company Nordtreat strengthens its growth by appointing Outi Kallio as the new CEO. Her era at Nordtreat will start from the turn of 2024/2025. Outi Kallio has a wealth of experience in commercial and industrial management, having held several key positions at Teknos Group.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240902513997/en/
The Finnish technology company Nordtreat strengthens its growth by appointing Outi Kallio as the new CEO. (Photo: Business Wire)
Outi Kallio has an extensive background in sales, HR, and marketing. She also has a proven track record of leading international teams. Currently, she holds the position of Global Commercial Director at Teknos Group.
"As Nordtreat continues to grow and evolve, we are thrilled to welcome Outi Kallio as our new CEO. Her diverse experience and proven leadership skills make her the ideal candidate to lead Nordtreat into its next chapter. We believe that Outi Kallio’s strategic vision and operational expertise will drive our company forward and enhance shareholder value," says Leif Frilund, Chairman of the Board of Nordtreat.
"With over a decade of experience in the coatings industry, I have seen a growing shift towards sustainable solutions, driven by increasing customer expectations. Nordtreat's commitment to bio-based technologies and its strong ethos of responsibility provides a solid foundation for scaling Finnish sustainability expertise into an international growth story. I am excited to join this team of top professionals and look forward to contributing to our shared success," Outi Kallio says.
As Nordtreat’s CEO, Outi Kallio will succeed Aki Borgentorp, who has led the company for ten years. These years have included the development of the first truly bio-based flame retardant for wood-based materials and the growth of a worldwide market presence.
"Over the past decade, Nordtreat has built a scalable platform for the development and production of bio-based flame retardants for wood-based materials. I am convinced that under Outi Kallio’s leadership, Nordtreat will continue to innovate and expand its presence in the market and make a significant impact in the construction materials industry," says Aki Borgentorp.
"On behalf of the Nordtreat board, I’d like to express our sincere gratitude to Aki Borgentorp for his remarkable achievement in building Nordtreat from scratch into a leading provider of new sustainable flame-retardant solutions. We wish Aki the best of success in his future endeavours," Leif Frilund says.
Nordtreat has also welcomed Dr Thomas Kostka, the Head of Corporate Venturing at Altana AG, to join the board of directors starting in August 2024. Additionally, Nordtreat has appointed Sakari Saarela, a partner in the UB FIGG Fund, as a board observer. Sampsa Auvinen, who has been on Nordtreat's board since 2022, will continue as UB FIGG's representative on the board. Sampsa Auvinen is also the Chairman of the Advisory Board of UB FIGG. Altana Group, the global leader in true specialty chemicals, and the Finnish sustainability fund UB Forest Industry Green Growth Fund (UB FIGG), a growth private equity fund investing in sustainable and resource-efficient forest and bio-based industries, announced an investment in Nordtreat in June 2024.
"We are happy to welcome Thomas Kostka to the board of directors at Nordtreat. He brings us a deep understanding of the industry and strategic insights that will be invaluable as we continue to grow," says Leif Frilund.
Nordtreat is a Finnish technology company founded in 2015, specializing in the development and production of environmentally friendly, high-performance flame retardants. Utilizing bio-based raw materials, Nordtreat's products comply with the latest fire protection regulations and have been used to protect over 2000 buildings worldwide. The company's flagship technology, NORFLAM®, is designed to provide superior fire protection while maintaining environmental sustainability. Nordtreat's innovative solutions are aimed at meeting the growing global demand for safer, more sustainable construction materials. www.nordtreat.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20240902513997/en/
Contacts
Leif Frilund
Chairman, Nordtreat
leif.frilund@walki.com
+358403543330
Aki Borgentorp
CEO, Nordtreat
aki.borgentorp@nordtreat.com
+358 400 366801
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 13:50:00 EEST | Press release
IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom